Aktienanalyse zu Arbutus Biopharma Corp (ABUS)ABUSArbutus Biopharma Corp

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, ABUS is not a strong buy due to its recent performance and technical indicators. The stock is trading at $4.22, which is below the analyst price target of $5.14, suggesting some upside potential. However, the RSI is at 38.6, indicating that the stock is nearing oversold conditions, but not yet in a strong buy zone. Additionally, the stock has experienced a 20-day change of -15.77%, reflecting recent downward pressure.

7 analysts cover ABUS: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 7.00.